STAT

DECEMBER 7, 2023

Patent & Trademark Office granted two more patents, but did not do so until 2008. The move meant that the company, which is now part of Bristol Myers Squibb, won several more years of valuable patent protection than it would have received had it applied for the extra patents when submitting its data to the FDA.

Drug Pricing 319

Drug Pricing Compounding Pharmaceutical Companies Pharmaceutical Companies 319

pharmaphorum

JULY 15, 2022

Teva has asked the Supreme Court to look at a judgment in a $235 million patent dispute with GSK that it claims could undermine the ability of generic drugmakers to bring new products to market, and thereby help reduce drug prices.

Labelling 52

Labelling Drug Pricing 52

Express Pharma

SEPTEMBER 6, 2023

In a bid to resolve both physical and financial restrictions inhibiting equitable access to quality medicines, the Jan Aushadhi scheme was launched in 2008 and envisaged the setting up of dedicated Janaushadhi Kendras to provide quality generic medicines at capped prices for the general public. appeared first on Express Pharma.

Insurance Coverage and Processing 59

Insurance Coverage and Processing Biosimilars Generic Medicine Drug Pricing 59

Safe Biologics

APRIL 25, 2023

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. First, the policy itself has built-in-problems. 2 Furthermore, cancer death rates per 100,000 are 1.6

Drug Pricing 130

Drug Pricing Biosimilars Vaccines 130

Safe Biologics

APRIL 25, 2023

By Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines (ASBM) ASBM recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the proposed Medicare Drug Price Negotiation Plan. First, the policy itself has built-in-problems. 2 Furthermore, cancer death rates per 100,000 are 1.6

Drug Pricing 130

Drug Pricing Biosimilars Vaccines 130

Pharmaceutical Technology

MAY 29, 2008

Andrew Witty took the helm of pharmaceutical giant GlaxoSmithKline in May 2008. PT: Given recent problems with a safety scare over diabetes drug Avandia and GSK’s guidance for a fall in 2008 earnings, what do you envisage Witty’s top or first priorities will be in the new job?

Drug Pricing 40

Drug Pricing Diabetes Drug Development 40